Openbookopenbook
Equity
BSX
+0.0 · +0.00%
USD · NYSE

Boston Scientific Corp(BSX) Stock Analysis | Healthcare

USD --+0.00%
Reward71High
Risk25Low
75%Data
Strong 18% profit margin
Quality Compounder
Market Cap:73.00Bn
ⓘ
Reward Rating
71
High
Reward Assessment
75% data coverage
Top 25% of stocksView factors
ⓘ
Risk Rating
25
Low
Risk Assessment

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on BSX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for BSX, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $62.69.

What is Boston Scientific Corp?

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.

BSX · Verdict

Strong reward · low risk

BSX scores well on profitability and cash flow with no major weaknesses flagged in the model.

Based on 88% data coverage

BSX · Verdict

What’s working & what to watch

Strengths 5

  • Profitability92/100

    14% net margin · 15% ROE

  • Cash flow85/100

    18% free-cash-flow margin

  • Volatility80/100

    Top decile vs peers

  • Valuation74/100

    P/E 15.3× · PEG 0.72

  • Growth73/100

    Rev +16.5% CAGR · earnings +60.5%

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Boston Scientific Corp?

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 73.00B, and a P/E ratio of 20.4x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: High (71)

The scoring profile indicates a strong reward potential, driven primarily by profitability and valuation. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Medical Devices names that are close enough in size to make side-by-side comparison useful.

SEMHFLarge Cap / 56.5B market cap
Siemens Healthineers AG
Compare
EWLarge Cap / 51.8B market cap
Edwards Lifesciences Corp
Compare
MDTLarge Cap / 116B market cap
Medtronic PLC
Compare
Company Information
SectorHealthcare
IndustryMedical Devices
Market Cap73.00B
P/E Ratio20.3927
Dividend YieldN/A
Beta0.566
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
2178,214 shares
$16.8M
0
9-12months
262,891 shares
$6.2M
0
16 disclosures without share count
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.